Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2013

View Archived Issues

Ascendis Pharma discloses novel treprostinil prodrugs

CSIR prepares new agents for tuberculosis

Scientists at the Universite Laval divulge novel anticancer agents

Cellceutix initiates agreement to acquire a new compound

BioTime and LifeMap Sciences enter into data mining collaboration

Starpharma reports animal data for dendrimer-based formulation of doxorubicin

Advanced Cell Diagnostics and Johns Hopkins sign agreement for cancer immunotherapy

Roche synthesizes new BTK inhibitors

Roche presents novel tyrosine-protein kinase inhibitors

Potent efficacy for faldaprevir demonstrated in the STARTverso 4 trial

Brodalumab demonstrates efficacy in patients with psoriasis

OPKO Health completes acquisition

Discgenics' injectable disc-derived stem cell therapy shows promising results in animals

FDA advisory committee votes against approval of Depomed's Sefelsa

Silence Therapeutics gains clearance for phase Ib/IIa trial of ATU-027 in pancreatic cancer

Application for additional indication of Glivec withdrawn in Japan

Phase I/II trial of DCVax-Direct to begin within next 60 days

Rbm5 proves essential for the progression of spermatogenesis

Dicer1 gene linked to sperm maturation

Roche obtains E.U. approval for Perjeta

FcERI-mimetic peptide demonstrates protection from anaphylaxis in vivo

FDA issues second complete response letter for Xarelto

FDA committee votes on approval of low-dose mesylate salt of paroxetine

Radiotracer [64Cu]-TP-3805 distinguishes benign from breast cancer tissues

Galectin Therapeutics receives FDA clearance for trial of GR-MD-02

Merck Serono creates spin-off company focused on gastrointestinal disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...